Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

25. August 2025 09:00 ET | Quelle: Muscular Dystrophy Association

Muscular Dystrophy Association Launches #MDAstrong Campaign in September During Historic 75th Anniversary, Kicking Off on Labor Day Weekend

New York, Aug. 25, 2025 (GLOBE NEWSWIRE) -- This September, the Muscular Dystrophy Association (MDA) is launching its milestone #MDAstrong campaign during a historic moment for the organization: its...
19. August 2025 13:28 ET | Quelle: Charitable Impact

Charitable Impact Pays Tribute to NHL’s Mark Kirton Following His Passing

VANCOUVER, BC, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Charitable Impact today pays tribute to former NHL player and ALS champion Mark Kirton, who passed away on August 17, 2025. Diagnosed with ALS in...
14. August 2025 07:00 ET | Quelle: Athira Pharma, Inc.

Athira Pharma Presents ATH-1105 Phase 1 Trial Results at ALS Nexus 2025

BOTHELL, Wash., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to restore neuronal health and...
30. Juli 2025 09:24 ET | Quelle: Trethera Corporation

FDA Provides Trethera Clearance to Initiate TRE-515 Clinical Trial in Healthy Volunteers to Study Food Effect and Biomarkers

Creates platform for precision dosing, companion diagnostics, streamlined development, and broader use across cancer and autoimmune diseases.
30. Juli 2025 09:00 ET | Quelle: Muscular Dystrophy Association

Registration Now Open for the 2026 MDA Clinical & Scientific Conference Where Global Leaders in Neuromuscular Disease Research & Care Unite to Drive the Next Breakthroughs March 8-11 in Orlando, FL

New York, July 30, 2025 (GLOBE NEWSWIRE) -- The Muscular Dystrophy Association (MDA), leader and innovator of the largest global gathering of the neuromuscular disease community, announced today...
24. Juli 2025 01:57 ET | Quelle: AB Science

AB Science a obtenu l'autorisation de plusieurs pays européens pour initier l’étude confirmatoire de phase 3 avec le masitinib dans la SLA

COMMUNIQUÉ DE PRESSE AB SCIENCE A OBTENU L'AUTORISATION DE PLUSIEURS PAYS EUROPÉENS POUR INITIER L’ETUDE CONFIRMATOIRE DE PHASE 3 AVEC LE MASITINIB DANS LA SCLEROSE LATERALE AMYOTROPHIQUE CETTE...
24. Juli 2025 01:57 ET | Quelle: AB Science

AB Science has received approval from several European countries to initiate the confirmatory phase 3 study of masitinib in ALS

PRESS RELEASE AB SCIENCE HAS RECEIVED APPROVAL FROM SEVERAL EUROPEAN COUNTRIES TO INITIATE THE CONFIRMATORY PHASE 3 STUDY OF MASITINIB IN AMYOTROPHIC LATERAL SCLEROSIS THIS APPROVAL FOLLOWS PROTOCOL...
02. Juli 2025 14:00 ET | Quelle: MIT Sloan School of Management

Financing Innovation: Proposal for Novel Adaptive Platform Trial Fund Offers New Model for ALS Drug Development

Cambridge, Mass., July 02, 2025 (GLOBE NEWSWIRE) -- A team of researchers from the MIT Sloan School of Management, the Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital...
13. Mai 2025 11:00 ET | Quelle: Athira Pharma, Inc.

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

Data from Phase 1 clinical trial of ATH-1105 in healthy volunteers showed a favorable safety and tolerability profile; dose proportional pharmacokinetics and CNS penetration support continued clinical...
09. Mai 2025 16:05 ET | Quelle: Athira Pharma, Inc.

Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

Completed healthy volunteer Phase 1 clinical study of ATH-1105 as a potential treatment for amyotrophic lateral sclerosis (ALS); full healthy volunteer data expected in 2H25 On-track to enable...

Nächste Seite